Plecanatide, an Oral Guanylate Cyclase C Agonist Acting Locally in the Gastrointestinal Tract, Is Safe and Well-Tolerated in Single Doses

@article{Shailubhai2013PlecanatideAO,
  title={Plecanatide, an Oral Guanylate Cyclase C Agonist Acting Locally in the Gastrointestinal Tract, Is Safe and Well-Tolerated in Single Doses},
  author={Kunwar Shailubhai and Stephen Comiskey and John A. Foss and Rong Feng and Laura N. Barrow and Gail M. Comer and Gary S. Jacob},
  journal={Digestive Diseases and Sciences},
  year={2013},
  volume={58},
  pages={2580-2586}
}
PurposePlecanatide, an analogue of uroguanylin, activates the guanylate cyclase C (GC-C) receptor found on the GI mucosal epithelial cells, leading to secretion of fluid, facilitating bowel movements. Plecanatide is being investigated as a potential treatment for constipating GI disorders. The aim of this investigation was to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of plecanatide in healthy volunteers.MethodsA total of 72 healthy… 
Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation
TLDR
Plecanatide is a luminally acting secretagogue that is efficacious and safe for the treatment of CIC and reported high levels of satisfaction and improved QOL and desire to continue treatment.
A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
TLDR
Results suggest that plecanatide will be a useful treatment option in the management of CIC and significantly improved constipation and its related symptoms with a low rate of adverse events.
Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome
  • P. Miner
  • Medicine
    Expert opinion on pharmacotherapy
  • 2018
TLDR
Plecanatide is the first uroguanylin analog that stimulates GC-C receptors on gastrointestinal mucosa with pH-sensitive receptor binding, which activates intracellular conversion of GTP to cGMP resulting in the stimulation of intestinal fluid secretion.
Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions.
TLDR
Overall, data support a secretory diathesis in IBS-D and the medication linaclotide was developed as a treatment for chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C).
Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
TLDR
This is the first-ever study reporting the therapeutic utility of GC-C agonists as a new class of orally delivered and mucosally active drug candidates for the treatment of inflammatory bowel diseases.
Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases
TLDR
Preclinical and clinical trials focused on assessment of therapeutic properties of synthetic agonists of uroguanylin, plecanatide, and SP‐333 are currently tested as a potential therapeutic in diseases related to constipation and SP-333 is a promising drug in ulcerative colitis treatment.
Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders
TLDR
This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.
Plecanatide for the treatment of constipation-predominant irritable bowel syndrome
  • P. Miner
  • Medicine
    Expert review of gastroenterology & hepatology
  • 2020
TLDR
All clinical trial results supporting approval of plecanatide in IBS-C are reported, evaluated and interpreted in the context of the complex pathophysiology of functional diseases and the barriers that must be overcome for appropriate protocol design and conduct.
Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
TLDR
Clinical data from studies of recently approved drugs for CIC are utilized to construct a platform for thoughtful understanding of CIC and of how changes in investigation guidelines influence the interpretation of study data and guide symptom management.
Therapeutically targeting guanylate cyclase‐C: computational modeling of plecanatide, a uroguanylin analog
TLDR
Molecular dynamics simulations compared the stability of plecanatide and linaclotide to STh, a synthetic analog of STh that activates GC‐C receptor activation in this region would stimulate intraluminal fluid secretion, potentially relieving symptoms associated with CIC and IBS‐C.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
  • L. Forte
  • Biology, Medicine
    Pharmacology & therapeutics
  • 2004
Therapeutic applications of guanylate cyclase-C receptor agonists.
  • K. Shailubhai
  • Biology, Medicine
    Current opinion in drug discovery & development
  • 2002
TLDR
Recent findings that expression of uroguanylin and guanylin is dramatically reduced in polyps and colon carcinoma tissues further support the notion that these peptide hormones are important modulators or mediators of signaling pathways leading to the processes involved in carcinogenesis and inflammatory disorders.
Two randomized trials of linaclotide for chronic constipation.
TLDR
In these two 12-week trials, linaclotide significantly reduced bowel and abdominal symptoms in patients with chronic constipation.
Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity.
TLDR
It is concluded that guanylin and uroguanylin evolved distinctly different structures, which enables both peptides to regulate, in a pH-dependent fashion, the activity of receptors that control intestinal salt and water transport via cGMP.
Lubiprostone: A Chloride Channel Activator for Treatment of Chronic Constipation
TLDR
Lubiprostone may be a reasonable alternative for use in patients who either fail or are intolerant of standard therapy for chronic constipation and head-to-head comparison studies with conventional therapy are needed to contrast clinical efficacy and safety of this medication.
Emerging Pharmacologic Therapies for Irritable Bowel Syndrome
TLDR
With more data obtained from phase 2 and 3 trials, it is expected other classes of medications, including bile acid modulators, anti-inflammatory agents, visceral analgesics, and newer centrally acting agents to be efficacious and enter the armamentarium for the treatment of IBS in the future.
Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia
TLDR
Dyspeptic patients with functional dyspepsia have increased sensitivity to both gastric distension and intraduodenal lipid, and in contrast to controls, lipid sensitizes their stomachs to distension.
Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome
  • M. Camilleri
  • Medicine
    Clinical pharmacology and therapeutics
  • 2012
Novel approaches are in development (GI) to treat lower functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), functional constipation, and functional diarrhea, which arise
Core Aspects of Clinical Development and Trials in Chronic Idiopathic Constipation
TLDR
A randomized, placebo-controlled phase 3 trial of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain and the effect of tegaserod in chronic constipation is presented.
...
1
2
...